Effects of valproic acid and magnesium sulphate on rocuronium requirement in patients undergoing craniotomy for cerebrovascular surgery

British Journal of Anaesthesia

Volumn 109, Issue 3, 2012, Pages 407-412

  Kim, M H ^a   Hwang, J W ^a   Jeon, Y T ^a   Do, S H ^a  

^a Seoul National University Bundang Hospital   (South Korea)

Author keywords

anti convulsant, valproic acid; ions, magnesium; neuromuscular block, rocuronium

Indexed keywords

ANTIEMETIC AGENT; MAGNESIUM SULFATE; NICARDIPINE; ROCURONIUM; SODIUM CHLORIDE; VALPROIC ACID;

ADULT; ARTICLE; CEREBROVASCULAR SURGERY; CONTINUOUS INFUSION; CONTROLLED STUDY; CRANIOTOMY; DOUBLE BLIND PROCEDURE; DRUG USE; FEMALE; HEART RATE; HUMAN; MAJOR CLINICAL STUDY; MALE; MEAN ARTERIAL PRESSURE; NAUSEA; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SHIVERING; TREATMENT OUTCOME; VOMITING;

EID: 84865249376     PISSN: 00070912     EISSN: 14716771     Source Type: Journal    
DOI: 10.1093/bja/aes218     Document Type: Article

References (24)

1. Naguib M, Lien C. Pharmacology of muscle relaxants and their antagonists. In: MILLER RD, ed. Miller's Anesthesia. Philadelphia: CHURCHILL Livingstone Elsevier, 2009; 859-911
2. Terbach N, Shah R, Kelemen R, et al. Identifying an uptake mechanism for the antiepileptic and bipolar disorder treatment valproic acid using the simple biomedical model dictyostelium. J Cell Sci 2011; 124: 2267-76
3. Na HS, Lee JH, Hwang JY, et al. Effects of magnesium sulphate on intraoperative neuromuscular blocking agent requirements and postoperative analgesia in children with cerebral palsy. Br J Anaesth 2010; 104: 344-50
4. Fuchs Buder T, Claudius C, Skovgaard L, Eriksson L, Mirakhur R, Viby Mogensen J. Good clinical research practice in pharmacodynamic studies of neuromuscular blocking agents II: The Stockholm revision. Acta Anaesthesiol Scand 2007; 51: 789-808
5. Cerveny L, Svecova L, Anzenbacherova E, et al. Valproic acid induces CYP3A4 and MDR1 gene expression by activation of constitutive androstane receptor and pregnane X receptor pathways. Drug Metab Dispos 2007; 35: 1032-41
6. Smit JW, Duin E, Steen H, Oosting R, Roggeveld J, Meijer DK. Interactions between P-glycoprotein substrates and other cationic drugs at the hepatic excretory level. Br J Pharmacol 1998; 123: 361-70
7. Proost JH, Eriksson LI, Mirakhur RK, Roest G, Wierda JM. Urinary, biliary and faecal excretion of rocuronium in humans. Br J Anaesth 2000; 85: 717-23
8. Driessen JJ, Robertson EN, Booij LH, Vree TB. Accelerated recovery and disposition from rocuronium in an end-stage renal failure patient on chronic anticonvulsant therapy with sodium valproate and primidone. Br J Anaesth 1998; 80: 386-8
9. Soriano SG, Sullivan LJ, Venkatakrishnan K, Greenblatt DJ, Martyn JA. Pharmacokinetics and pharmacodynamics of vecuronium in children receiving phenytoin or carbamazepine for chronic anticonvulsant therapy. Br J Anaesth 2001; 86: 223-9
10. Soriano SG, Martyn JA. Antiepileptic-induced resistance to neuromuscular blockers: Mechanisms and clinical significance. Clin Pharmacokinet 2004; 43: 71-81
11. Wen X, Wang JS, Kivisto KT, Neuvonen PJ, Backman JT. In vitro evaluation of valproic acid as an inhibitor of human cytochrome P450 isoforms: Preferential inhibition of cytochrome P450 2C9 (CYP2C9). Br J Clin Pharmacol 2001; 52: 547-53
12. Eyal S, Lamb JG, Smith-Yockman M, et al. The antiepileptic and anticancer agent, valproic acid, induces P-glycoprotein in human tumour cell lines and in rat liver. Br J Pharmacol 2006; 149: 250-60
13. Nguyen A, Ramzan I. In vitro neuromuscular effects of valproic acid. Br J Anaesth 1997; 78: 197-200
14. Lazarowski A, Czornyj L, Lubienieki F, Girardi E, Vazquez S, D'Giano C. ABC transporters during epilepsy and mechanisms underlying multidrug resistance in refractory epilepsy. Epilepsia 2007; 48 (Suppl. 5): 140-9
15. Herroeder S, Schonherr ME, De Hert SG, Hollmann MW. Magnesium- essentials for anesthesiologists. Anesthesiology 2011; 114: 971-93
16. Ryu JH, Kang MH, Park KS, Do SH. Effects of magnesium sulphate on intraoperative anaesthetic requirements and postoperative analgesia in gynaecology patients receiving total intravenous anaesthesia. Br J Anaesth 2008; 100: 397-403
17. Lambert CR, Hill JA, Nichols WW, Feldman RL, Pepine CJ. Coronary and systemic hemodynamic effects of nicardipine. Am J Cardiol 1985; 55: 652-6
18. Ryu JH, Sohn IS, Do SH. Controlled hypotension for middle ear surgery: A comparison between remifentanil and magnesium sulphate. Br J Anaesth 2009; 103: 490-5
19. Dasgupta A, McLemore JL. Elevated free phenytoin and free valproic acid concentrations in sera of patients infected with human immunodeficiency virus. Ther Drug Monit 1998; 20: 63-7
20. Westermaier T, Stetter C, Vince GH, et al. Prophylactic intravenous magnesium sulfate for treatment of aneurysmal subarachnoid hemorrhage: A randomized, placebo-controlled, clinical study. Crit Care Med 2010; 38: 1284-90
21. Korenkov AI, Pahnke J, Frei K, et al. Treatment with nimodipine or mannitol reduces programmed cell death and infarct size following focal cerebral ischemia. Neurosurg Rev 2000; 23: 145-50
22. Takaku A, Shindo K, Tanaka S, Mori T, Suzuki J. Fluid and electrolyte disturbances in patients with intracranial aneurysms. Surg Neurol 1979; 11: 349-56
23. Czarnetzki C, Lysakowski C, Elia N, Tramer M. Time course of rocuronium induced neuromuscular block after pre treatment with magnesium sulphate: A randomised study. Acta Anaesthesiol Scand 2010; 54: 299-306
24. Gupta K, Vohra V, Sood J. The role of magnesium as an adjuvant during general anaesthesia. Anaesthesia 2006; 61: 1058-63